S&P 500   3,211.46 (-0.47%)
DOW   26,712.04 (-0.59%)
QQQ   258.60 (-0.88%)
AAPL   385.75 (-1.32%)
MSFT   204.18 (-1.86%)
FB   239.46 (-0.34%)
GOOGL   1,507.39 (-0.63%)
AMZN   3,010.00 (+0.04%)
NVDA   405.60 (-0.85%)
CGC   17.92 (-1.27%)
BABA   244.38 (-1.94%)
MU   50.02 (-0.97%)
GE   7.12 (-0.28%)
TSLA   1,518.99 (-1.75%)
AMD   54.57 (-1.39%)
T   30.31 (+1.00%)
ACB   12.09 (-6.06%)
F   6.85 (+1.63%)
GILD   76.11 (-0.70%)
DIS   119.49 (-1.17%)
NFLX   525.85 (+0.49%)
BAC   23.94 (-2.68%)
BA   180.99 (-3.70%)
S&P 500   3,211.46 (-0.47%)
DOW   26,712.04 (-0.59%)
QQQ   258.60 (-0.88%)
AAPL   385.75 (-1.32%)
MSFT   204.18 (-1.86%)
FB   239.46 (-0.34%)
GOOGL   1,507.39 (-0.63%)
AMZN   3,010.00 (+0.04%)
NVDA   405.60 (-0.85%)
CGC   17.92 (-1.27%)
BABA   244.38 (-1.94%)
MU   50.02 (-0.97%)
GE   7.12 (-0.28%)
TSLA   1,518.99 (-1.75%)
AMD   54.57 (-1.39%)
T   30.31 (+1.00%)
ACB   12.09 (-6.06%)
F   6.85 (+1.63%)
GILD   76.11 (-0.70%)
DIS   119.49 (-1.17%)
NFLX   525.85 (+0.49%)
BAC   23.94 (-2.68%)
BA   180.99 (-3.70%)
S&P 500   3,211.46 (-0.47%)
DOW   26,712.04 (-0.59%)
QQQ   258.60 (-0.88%)
AAPL   385.75 (-1.32%)
MSFT   204.18 (-1.86%)
FB   239.46 (-0.34%)
GOOGL   1,507.39 (-0.63%)
AMZN   3,010.00 (+0.04%)
NVDA   405.60 (-0.85%)
CGC   17.92 (-1.27%)
BABA   244.38 (-1.94%)
MU   50.02 (-0.97%)
GE   7.12 (-0.28%)
TSLA   1,518.99 (-1.75%)
AMD   54.57 (-1.39%)
T   30.31 (+1.00%)
ACB   12.09 (-6.06%)
F   6.85 (+1.63%)
GILD   76.11 (-0.70%)
DIS   119.49 (-1.17%)
NFLX   525.85 (+0.49%)
BAC   23.94 (-2.68%)
BA   180.99 (-3.70%)
S&P 500   3,211.46 (-0.47%)
DOW   26,712.04 (-0.59%)
QQQ   258.60 (-0.88%)
AAPL   385.75 (-1.32%)
MSFT   204.18 (-1.86%)
FB   239.46 (-0.34%)
GOOGL   1,507.39 (-0.63%)
AMZN   3,010.00 (+0.04%)
NVDA   405.60 (-0.85%)
CGC   17.92 (-1.27%)
BABA   244.38 (-1.94%)
MU   50.02 (-0.97%)
GE   7.12 (-0.28%)
TSLA   1,518.99 (-1.75%)
AMD   54.57 (-1.39%)
T   30.31 (+1.00%)
ACB   12.09 (-6.06%)
F   6.85 (+1.63%)
GILD   76.11 (-0.70%)
DIS   119.49 (-1.17%)
NFLX   525.85 (+0.49%)
BAC   23.94 (-2.68%)
BA   180.99 (-3.70%)
Log in

NASDAQ:LXRXLexicon Pharmaceuticals Stock Price, Forecast & News

$1.99
-0.07 (-3.40 %)
(As of 07/16/2020 01:38 PM ET)
Add
Compare
Today's Range
$1.99
Now: $1.99
$2.03
50-Day Range
$1.85
MA: $1.95
$2.19
52-Week Range
$1.13
Now: $1.99
$5.94
Volume6,961 shs
Average Volume737,862 shs
Market Capitalization$212.87 million
P/E Ratio3.21
Dividend YieldN/A
Beta1.16
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Read More
Lexicon Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$322.07 million
Cash Flow$1.78 per share
Book Value$1.10 per share

Profitability

Net Income$130.13 million

Miscellaneous

Employees202
Market Cap$212.87 million
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

How has Lexicon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Lexicon Pharmaceuticals' stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LXRX stock has decreased by 12.3% and is now trading at $1.99. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Lexicon Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Lexicon Pharmaceuticals.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Lexicon Pharmaceuticals.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Monday, April, 27th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.69) by $0.06. The biopharmaceutical company had revenue of $8 million for the quarter, compared to analyst estimates of $7.18 million. Lexicon Pharmaceuticals had a net margin of 26.59% and a return on equity of 125.61%. View Lexicon Pharmaceuticals' earnings history.

What price target have analysts set for LXRX?

6 brokerages have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their forecasts range from $2.10 to $9.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $4.53 in the next twelve months. This suggests a possible upside of 127.4% from the stock's current price. View analysts' price targets for Lexicon Pharmaceuticals.

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

Press coverage about LXRX stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news impact score of -1.9 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Lexicon Pharmaceuticals.

Are investors shorting Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,920,000 shares, an increase of 8.5% from the June 15th total of 10,060,000 shares. Based on an average daily volume of 929,400 shares, the days-to-cover ratio is presently 11.7 days. Currently, 10.6% of the company's stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Who are some of Lexicon Pharmaceuticals' key competitors?

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the following people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%), Envestnet Asset Management Inc. (0.08%), Diversified Trust Co (0.02%) and Investors Financial Group LLC (0.01%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats and Sam L Barker. View institutional ownership trends for Lexicon Pharmaceuticals.

Which major investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Wedbush Securities Inc., Diversified Trust Co, and Investors Financial Group LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, and Sam L Barker. View insider buying and selling activity for Lexicon Pharmaceuticals.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $1.99.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $212.87 million and generates $322.07 million in revenue each year. The biopharmaceutical company earns $130.13 million in net income (profit) each year or $1.35 on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is www.lexpharma.com.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.